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ABSTRACT
Helicobacter pylori (H. pylori) infection is still a big issue in gastroenterology field. Its relationship with 
gastrointestinal malignancies now is widely known and the extra-gastrointestinal manifestation of this epidemic 
bring new problems. Although the prevalence is decreasing in developed countries, the resistance rate of some 
strains to standard therapy needs more attention and new strategies. Recent epidemiology studies revealed that 
H. pylori infection is a specific population disease. Many trials and meta analyses revealed new evidences and 
horizons in the management of this infection. This review updated and highlighted pathophysiology, clinical 
aspect, and new epidemiology data on H. pylori infection which is published in the last five years.
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ABSTRAK
Infeksi Helicobacter pylori (H. pylori) masih merupakan permasalahan besar di bidang gastroenterologi. 
Hubungannya dengan keganasan saluran cerna saat ini telah dikenal secara luas dan manifestasinya di luar 
pencernaan pada epidemi ini membawa masalah baru. Meskipun prevalensinya menurun di negara-negara maju, 
namun tingkat resistensi dari beberapa terapi standar membutuhkan lebih banyak perhatian dan strategi baru. 
Penelitian epidemiologi baru-baru ini mengungkapkan bahwa infeksi H. pylori didapatkan pada populasi tertentu. 
Banyak percobaan dan metaanalisis yang mengungkapkan bukti dan wawasan baru dalam penatalaksanaannya. 
Ulasan ini memperbarui dan menyoroti patofisiologi, aspek klinis, dan data epidemiologi baru pada infeksi H. 
pylori yang telah dipublikasikan dalam lima tahun terakhir.
Kata kunci: Helicobacter pylori, memperbarui, epidemiologi
INTRODUCTION
Infection of Helicobacter pylori (H. pylori) is still 
a big problem in some areas.1,2 Not only dyspeptic 
symptoms that increase the number of consultation and 
referral to gastroenterologist and health cost, the risk 
for ulcers, gastric lymphoma, and gastric cancer also 
increase.3 Furthermore, H. pylori infection is reported 
to be associated with many extra-gastrointestinal 
manifestations, such as idiopathic thrombocytopenic 
purpura (ITP), unexplained iron deficiency anemia, 
cardiovascular disease (ischemic heart diseases), 
neurological disorders (i.e. stroke, Parkinson's disease, 
Alzheimer's disease), obesity, and skin disorders.4 From 
the discovery of H. pylori in 1983 as quoted by Fock 
et al, this infection has been recognized to be a global 
health problem.5 But, since the test of this infection is 
not easy and needs special tools, we are challenged to 
prove how big the problem in specific population is. 
It will impact the clinical recommendation and policy 
for screening and eradication programs.
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From old literatures, it has been said that the 
prevalence of H. pylori infection in developing 
countries is higher than in developed countries.6-8 
Prevalence in developed countries is 30-40% while 
in developing countries the prevalence reaches 80-
90%. About 10-20% from all infection will develop 
to gastroduodenal problems. In non-ulcer dyspepsia 
patients, the prevalence of H. pylori infection varies 
from 20-40% based on the diagnostic methods used 
in the study; serology, culture, or histopathology.6 In a 
multicenter study from Indonesia, from 550 dyspeptic 
patients who underwent endoscopy, H. pylori was 
found positive in 56 (10.2%) patients. The highest 
prevalence of H. pylori was found in patients from 
Jogjakarta (30.6%) and the lowest was in patients from 
Jakarta (8%).9
The correlation between H. pylori infection 
and gastric cancer is also a big concern.10 Global 
epidemiologic studies revealed that geographical 
differentiation influence the correlation between H. 
pylori infection and development of gastric cancer.10,11 
Many studies and reviews already proved and discussed 
about this phenomenon. We can resume that there are 
many factors, protective and predisposing, that lead to 
gastric cancer other than H. pylori infection itself, but 
still, the infection have an important role.12
Many developments in the field of H. pylori 
infection today endorse hundred studies all over the 
world to search new pathogenesis model, epidemiology 
phenomenon, best diagnostic and treatment for 
reducing the risk of malignancy complication in 
the latter day. All of these findings need efforts, 
hardwork, and dedication from researchers, clinicians, 
andepidemiologists. In fact, researches in this field 
never stop in the last 20 years. 
THE LIFE OF HELICOBACTER PYLORI IN HUMAN 
BODY
H. pylori can be called one of the most successful 
bacteria live in human because it survives from the 
most difficult situation, and colonizes in one half of 
the human population. Salama et al published the latest 
pathogenesis review about persistence strategies of 
H. pylori in humans' stomach.13 In the review, they 
discussed the pathogenesis of this microorganism and 
the mechanisms it uses to colonize gastric mucosa. 
They focus on the role of the virulence factors 
vacuolating cytotoxin A (VacA), cytotoxin-associated 
gene A (CagA), and cytotoxin-associated gene L 
(CagL), and describe the immunobiology of H. pylori 
infection. Besides virulence factors, these bacteria also 
manipulates the innate and adaptive immune systems 
of the host to promote its own persistence.13
The stomach is a hard niche for microorganism to 
live. H. pylori adheres to epithelial cells by producing 
adhesin. Adhesin binds to carbohydrate and lipid in 
epitelial cell membrane. H. pylori can only survive 
for a while (in minutes) in the lumen and must move 
to gastric epithelial surface. Urease enzyme produced 
by the bacteria raised the pH in the stomach to near 
neutral and the viscoelastic solution allowing H. pylori 
to live actively in the human gaster. The helical shape 
also enhanced the motility throughout this media. 
H. pylori also actively manage its interaction with 
the host epithelium to escape from the clearance by 
inflammation responses.13-15
Only few number of studies and reviews discuss 
the strategies of H. pylori to promote survival to 
face immune system. H. pylori creates proteins 
which neutralize reactive oxygen species.13 The 
microorganism also produces arginase to inhibit 
nitric oxide production by macrophage, neutrophil, 
and epithelial cell-derived nitric oxide synthase. 
By complex-genetic diversification, H. pylori also 
regulates natural ability to become more persistent, 
which is called chronically persistence, in the human 
stomach.13,14
Strains of H. pylori manipulate host tissues and 
give persistence in the epithelial cells of the gaster by 
secreting toxins. Two most important toxins produced 
are VacA and CagA.14 While VacA gene determines 
the severity of infection of the bacteria, CagA is 
dominant to give risk for gastric cancer to the patient. 
CagA acts as oncogenic protein and also have a vital 
role in colonization of H. pylori. The virulence of 
the microorganism depends on these proteins. Latest 
studies in the field of molecular gastroenterology give 
attention to the VacA and CagA interaction as one of 
the most important ‘missing link’ for the oncogenesis 
of gastric lymhoma and gastric cancer.13
Salama et al also reported the way of H. pylori 
elaborate strategies to evade and subvert host immune 
defences. H. pylori can avoid detection by several 
types of pattern recognition receptors (PRRs) which 
are very crucial for recognition of gram-negative 
enteropathogens.13 Two mechanisms used by this 
bacteria are evasion of innate immune detection 
by pro-inflammatory toll-like receptors (TLRs) 
and the preferential activation and manipulation of 
antiinflammatory TLRs and CLRs (C-type lectin 
receptors). All of these strategies make H. pylori 
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stronger and persist in the stomach, as well as more 
virulence and tend to higher the risk of malignancies 
in human gastrointestinal tract.15
WHAT EPIDEMIOLOGIC STUDIES TELL US ABOUT?
By searching database of medical publications, 
in only one year, there are not less than 25 new 
publications concerning about epidemiologic studies 
of H. pylori infection all over the world. Several 
things can be concluded from all of the studies: 1) 
social, ethnicity, and geographic difference can differ 
the prevalence of H. pylori infection in human; 2) as 
mentioned before, not only the infection itself gives the 
risk for gastric malignancies, but many other factors 
contribute to give the outcome of gastric cancer and 
gastric lymphoma. Last but not least, prevalence 
can vary by using difference diagnostic methods or 
definition (serology, culture, and histopathology), make 
us tobe very careful when broadcasting epidemiologic 
data of H. pylori infection.12
Prevalence of H. pylori infection worldwidely 
varies from 13 to 92% due to where the study was 
conducted.6 Developing countries suffer more from 
this infection than the developed one.16 Africa and 
East Asian has the highest prevalence while American 
and European countries has low prevalence. It is 
resumed that level of education and socio-economic 
stratification strongly correlated with the infection.6,7,17
By serological methods, there is a decrease of 
prevalence of H. pylori infection worldwide. From 
nationalpopulation studies in East Asian countries, 
such as Japan, Korea, Taiwan, and Indonesia, the 
seroprevalence of H. pylori has decreased in the last 
ten years. These separated studies has been concluded 
in Asia Pacific Consensus Guideline for Helicobacter 
pylori infection that the prevalence of the infection 
has been declining in the region.5 This epidemiology 
phenomenon was due to the successful screening 
program and treatment of the infection globally. As the 
burden decreased, the risk of peptic ulcers and gastric 
cancer in numerous countries has also been reduced. 
However, not all areas are the same. In Indonesia, there 
was decreased prevalence of H. pylori infection in 8 
year-period but there was no decreased prevalence of 
intestinal metaplasia and gastric cancer.9
Despite the decrease of the prevalence worldwidely, 
there are some issues of therapy failure in several 
studies.18,19 This is caused by resistance of some 
strains to antimicrobial, especially metronidazole 
and clarythromycin, in some populations. Generally, 
the resistance rate to clarythromycin is 17.2%, while 
metronidazole 26.7%, amoxicillin 11.2%, levofloxacin 
1.2%, and combination of antibiotics 9.6% rate of 
resistancy.20
Decrease of successful rate and increase prevalence 
of H. pylori resistant strains make treatment of H. 
pylori infection still challenging.21 At a glance, it is 
contradictive with the burden reduction in developed 
countries. However, if we stratify the resistance 
problems, we can see that this majority happened in 
developing countries. It is strongly recommended 
that study and program of eradication and solution of 
resistance problemsare directed in specific population.22 
It will save a lot of study fund. 
Selective populations in the same geographic area 
also have difference prevalence of H. pylori infection. 
Study by den Hollander et al revealed that despite of the 
declining of H. pylori infection in developed countries, 
the immigrants in these countries have higher number 
of prevalence, contributed to the actual epidemiology 
data in the region.23 The study in multi-ethnic European 
city gave a big deviation between Dutch versus non-
Ducth H. pylori infection prevalence (24% vs. 64%). 
This phenomenon is very important for public health 
programs, that screening and eradication programs not 
always similar for all of the population in one country, 
but must be selected in sub-population. This is also due 
to the variation of strains of H. pylori found in specific 
population or ethnicity worldwidely.14
It has been concluded from many studies that 
infection of H. pylori has strong (causality) link 
with gastric cancer.11 However, there are notable 
paradoxical epidemiology phenomenon that in some 
region, high prevalence of H. pylori infection is not 
followed by high incidence of gastric cancer. Africa 
has the highest prevalence of H. pylori infection 
but very low incidence of gastric cancer. The same 
phenomenon happen in India. Goh et al studied about 
this phenomenon in his country which has three major 
ethnicity; Indian, Chinese, and Malay decent.22 The 
study revealed that among the three ethnicity, Indian 
decent has the highest prevalence of H. pylori infection, 
but low incidence of gastric cancer, while Malay decent 
has either low prevalence of infection and also low 
incidence of gastric cancer.22,24
Many reviews hypothesize that trias Gordon, 
interaction between host, bacterial, and environment, 
strongly occur in the event of gastric cancer and 
its correlation with H. pylori infection. From the 
prespective of the bacteria, virulence factors of 
CagA with East Asian type (EPIYA-D) present in 
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Chinese population, while Western type (EPIYA-C) 
predominantly occur in Indian population.25,26 H. pylori 
also interacts with hosts who are susceptible to have 
chronic inflammation, atrophy of gastric mucosa, and 
development of cancer. Finally, many factors interact 
in the event of gastric cancer. Shortly, in epidemiology 
terminology, helicobacter infection is asufficient factor 
for gastric cancer.
CURRENT CLINICAL ISSUES OF HELICOBACTER 
PYLORI INFECTION
There are three guidelines which are used globally 
to manage H. pylori infection; Maastricht IV/Florence 
Consensus, American College of Gastroenterology 
(ACG) Guideline on the Management of H. pylori 
infection, and Second Asia-Pacific Consensus 
Guidelines for H. pylori infection.2,5,27,28 National 
guidelines such as Brazilian and Indonesian adapted 
these established guidelines. These three guidelines 
are a must read consensus for all clinicians treating 
H. pylori infection patient.29,30Among them, the ACG 
Guideline, which published in American Journal 
of Gastroenterology, remains the eldest consensus, 
but still relevant for clinicians all over the world. 
Maastricht IV/Florence Consensus was first published 
in 2010, and was republished in Gut in 2012.27 For 
Asian countries where the prevalence of H. pylori 
is high, they can alsouse the Second Asia-Pacific 
Consensus Guidelines for H. pylori infection. The 
consensus conference was held in 2008 in Bangkok. 
The guidelines was first published in Journal of 
Gastroenterology and Hepatology in 2009.5
The basic principles to test and treat H. pylori from 
the three consensus was relatively the same. From these 
guidelines, a test-and-treat strategy is appropriate for 
uninvestigated dyspepsia inpopulations where the H. 
pylori prevalence is high (> 20%). This approach is 
subject to patients with alarming symptoms or older 
patients (high risk for cancer). It should be kept in mind 
that main non-invasive tests that can be used for the 
test-and-treat strategy are the urea breath test (UBT) 
and monoclonal stool antigen tests. Certain validated 
serological tests can also be used. UBT and monoclonal 
stool antigen tests is also the appropriate test to confirm 
the eradication of H. pylori infection. The diagnostic 
test of H. pylori can only be performed if there is a plan 
to offer a treatment for positive results.26
Indications for treating H. pylori infection are 
also the same in these three guidelines; peptic 
ulcer disease, mucosa-associated lymphoid tissue 
lymphoma (MALToma), atrophic gastritis, history 
of gastric cancer resection, history of gastric cancer 
in the family, patient’s wishes, non-ulcer dyspepsia, 
before starting long-term aspirin therapy for high risk 
for ulcer patients, gastroesophageal reflux disease 
(GERD) requiring long-term proton pump inhibitor, 
and community prevention for gastric cancer in the 
region with high incidence of gastric cancer.5 In ACG 
guideline, there is a separation of established and 
controversial indication for diagnostic and treatment of 
H. pylori infection, with the controversial indications 
are persons using non-steroidal anti-inflammatory 
drugs (NSAIDs), unexplained iron deficiency anemia, 
GERD, and non-ulcer dyspepsia.2
Based on ACG guideline on the management of 
H. pylori, first-line regimens for H. pylori eradication 
are standard dose of proton pump inhibitor (PPI) 
twice daily, clarythromycin 500 mg twice daily, and 
amoxicillin 1,000 mg twice daily (duration 10-14 days), 
or standard dose PPI twice daily, clarythromicyn 500 
mg twice daily, and metronidazole 500 mg twice daily 
(duration 10-14 days), or bismuth subsalicylate 525 
mg fourth daily, metronidazole 250 mg fourth daily, 
tetracycline 500 mg fourth daily, and standard dose PPI 
fourth to twice daily (duration 10-14 days), or PPI + 
amoxicillin 1000 mg twice daily (for 5 days) followed 
by PPI, clarythromycin 500 mg, and tinidazole 500 
mg twice daily (for 5 days).2 In second Asia Pacific 
Consensus Guideline for H. pylori Infection, triple 
therapy with clarythromycin and amoxicillin for 7 
days is the choice among several first-line regimens. 
The slight difference with the ACG guideline of the 
management of Helicobacter pylori is the duration of 
the therapy, which is 7-14 days according to the Asian 
Pacific Consensus for Helicobacter pylori Infection.5 
For clinicians, we must consider the therapy duration 
with cost-benefit analysis. 
From meta-analysis studies from global population, 
it is stated that a 10-day treatment improves the 
eradication rate by 4% and a 14-day treatment improves 
the eradication rate by 5-6%, in comparison to a 7-day 
treatment. However, for the single Asian study in the 
meta-analysis that compared 14- with 7-day treatment, 
there was no difference in H. pylori eradication rates.21 
It is concluded in the guideline that there is only minor 
statistical differences between 14- and 7-day treatment 
and the choice for duration requires cost-effective and 
compliance considering decision.5
Resistance issue is a bad news in the success 
story of declining prevalence of H. pylori infection 
worldwide.18-20 Although the prevalence is also reduced, 
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Asian countries have the highest burden of resistancy 
compared to Western countries.5 Clarythromycin and 
metronidazole are the two antimicrobials that faced 
the highest resistancy issue. This phenomenon reduced 
the efficacy of PPI-based triple therapy. There are 
insufficient data to recommend sequential therapy 
as an alternativeto first-line therapy in Asia. Salvage 
therapy for the infection include; (a) standard triple 
therapy that has not been previously used; (b) bismuth-
based quadruple therapy; (c) levofloxacin-based triple 
therapy; (d) rifabutin-based triple therapy. Agreed 
with Asian statement, ACG also stated that there 
are no adequate evidences to support which salvage 
therapy is better than the others. Since patients usually 
get triple therapy with clarythromycin as previous 
treatment, the treatment of choice for salvage therapy 
is bismuth-quadruple therapy containing tetracycline 
and metronidazole.5
Another highlight in the therapy of H. pylori 
infection is the use of probiotics to improve 
eradication.31-33 In these three guidelines, only 
Maasctrich consensus stated about the use of probiotics 
with the recommendation D (expert opinion without 
explicit critical appraisal or based on physiology, 
bench research or ‘first principles’), while ACG and 
Asia Pacific guideline did not mention about probiotics 
at all.26 The consensus stated thatcertain probiotics 
and prebiotics show promising results as an adjuvant 
treatment in reducing side effects.
Abdullah et al stated that there are four protective 
mechanisms of probiotics in the context of H. pylori 
infection, which are producing antimicrobial substance, 
stabilizing the mucosal barier of the stomach, 
preventing adhesion of H. pylori, and modifying host 
immune responses. SCFAs and bacteriocin produced 
by probiotics impair the growth of bacteria. Probiotics 
also inhibit the colonization of H. pylori, and reduce 
tumor necrosis factor and interleukin-8 which act as 
the pro-inflammatory cytokines.34
Lactoferrin and Lactobacilli are two probiotics 
which often used in several trial to increase successful 
rate of Helicobacter pylori eradication treatment.27,32,33 
From the study done by Lesbros-Pantoflickova et al, 
long-term intake of products containing probiotic 
strains may have a favorable effect on H. pylori 
infection in humans, particularly by reducing the 
risk of developing disorders associated with high 
degrees of gastric inflammation.35 Recently, two meta-
analyses support the evidence of adding probiotics 
in the regimens can increase the efficacy of PPI-
clarythromycin containing triple therapy. However, 
lack quality control of the trials need clarification from 
other studies in the future.26
CONCLUSION
Before 1980s, no one could ever think about 
species which could live in human gaster. For the 
study which led on behalf public health, we are now 
celebrating 30 years discovery of H. pylori by Barry 
Marshall and Robbin Warren. Many studies, methods, 
and developments have been made in the last thirty 
years, but the escalation happened in the last ten 
years. There are some strategies made by the bacteria 
to ‘keep safe’ in human stomach, but at the same 
time, it develops higher virulence factors to human 
body. Epidemiology study always beneficial for the 
community and molecular mapping of the infection, 
along with the beneficial impacts of treatment program, 
resistancy issues, and eradication monitoring. Last 
but not least, the comparison of three most influential 
guidelines used to manage H. pylori clinically need to 
be understood, and as a clinician, we must adopt these 
statements carefully, with the clinical critical thinking. 
Use of probiotics is the latest hot issue now. We can 
predict in the future guidelines, probiotics will be 
given bigger portion since the molecular and clinical 
evidences supporting its benefit growing unstoppable.
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